VIATRIS INC. Income (Loss) from Equity Method Investments
VIATRIS INC. (VTRS) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2024-02-28
- VIATRIS INC. income (loss) from equity method investments for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. income (loss) from equity method investments for the quarter ending 2022-12-31 was $0.00.
- VIATRIS INC. income (loss) from equity method investments for the quarter ending 2022-09-30 was $0.00.
- VIATRIS INC. income (loss) from equity method investments for the quarter ending 2022-06-30 was -$100.00K.
- VIATRIS INC. income (loss) from equity method investments for fiscal 2023 was $0.00.
- VIATRIS INC. income (loss) from equity method investments for fiscal 2022 was $0.00.
- VIATRIS INC. income (loss) from equity method investments for fiscal 2021 was -$61.90M.
- VIATRIS INC. income (loss) from equity method investments for fiscal 2020 was -$48.40M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-28 | |||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | -$100.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | -$100.00K derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$100.00K derived: sum of 2 quarters · filed 2022-11-07 | $0.00 10-Q · filed 2022-11-07 | -$9.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | -$9.70M derived: sum of 3 quarters · filed 2024-02-28 | -$27.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-08 | -$9.60M derived: sum of 2 quarters · filed 2024-02-28 | -$27.20M derived: sum of 3 quarters · filed 2024-02-28 | -$43.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$9.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$27.30M derived: sum of 2 quarters · filed 2024-02-28 | -$44.00M derived: sum of 3 quarters · filed 2024-02-28 | -$61.90M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$17.60M 10-Q · filed 2022-11-07 | -$34.30M derived: sum of 2 quarters · filed 2022-11-07 | -$52.20M 10-Q · filed 2022-11-07 | -$63.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$16.70M 10-Q · filed 2022-08-08 | -$34.60M 10-Q · filed 2022-08-08 | -$45.60M derived: sum of 3 quarters · filed 2023-02-27 | -$48.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$17.90M 10-Q · filed 2022-05-09 | -$28.90M derived: sum of 2 quarters · filed 2023-02-27 | -$31.80M derived: sum of 3 quarters · filed 2023-02-27 | -$49.00M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$13.90M derived: sum of 2 quarters · filed 2023-02-27 | -$31.10M derived: sum of 3 quarters · filed 2023-02-27 | -$48.40M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$2.90M 10-Q · filed 2021-11-08 | -$20.10M derived: sum of 2 quarters · filed 2021-11-08 | -$37.40M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$17.20M 10-Q · filed 2021-08-09 | -$34.50M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$17.30M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$62.10M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$78.70M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |